Braincool AB has scored a breakthrough device designation from the U.S. FDA for its Cooral system, a medical cooling technology for therapeutic hypothermia and oncology. The status acknowledges Cooral’s potential to prevent oral mucositis (OM), a complication of chemotherapy.
A study led by scientists at the Korean Research Institute of BioScience and Biotechnology in Daejeon is the first to demonstrate that Dilp8/INSL3-Lgr3/8-NUCB, neuropeptide y signaling may be a potential therapeutic target in cancer anorexia and cachexia, which is associated with increased cancer mortality.
Molecular Templates Inc., of Austin, Texas, has signed an R&D collaboration with Bristol Myers Squibb Co. (BMS) worth $70 million up front and potential development, regulatory and sales milestone payments of up to $1.3 billion. Molecular Templates will work on therapies designed for unnamed oncology targets to kill targeted cells by forcing receptor internalization, delivering payloads and enzymatically inactivating ribosomes.
Twenty years to the month after the completion of the draft sequence of the human genome, the Human Genome Project and follow-on projects like The Cancer Genome Atlas are underpinning advances in precision medicine.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including: Aveo, Cardiff, Clovis, Essa, Infinity, Noxopharm.
RSS
